
Commentary|Videos|March 19, 2026
Navigating the New Era of T-Cell Engaging Treatments for Lymphoma
Author(s)Matthew J. Matasar, MD
Fact checked by: Paige Britt
Lymphoma care shifts beyond harsh chemo as CAR T, bispecific antibodies, and antibody-drug conjugates deliver stronger, safer treatment.
Advertisement
The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategies. In an interview with Targeted Oncology, Matthew J. Matasar, MD, chief of the Division of Blood Disorders at the Rutgers Cancer Institute, explores the rapid pace of innovation defining modern hematologic oncology, specifically the clinical move toward a "win-win" scenario: achieving superior efficacy while simultaneously reducing treatment-related toxicity.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Real-World Data Confirm Alectinib's Edge Over Crizotinib in ALK+ NSCLC
5
































